356 related articles for article (PubMed ID: 25468994)
21. RETRACTED: An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase.
Littlefield P; Moasser MM; Jura N
Chem Biol; 2014 Apr; 21(4):453-458. PubMed ID: 24656791
[TBL] [Abstract][Full Text] [Related]
22. EGF and NRG induce phosphorylation of HER3/ERBB3 by EGFR using distinct oligomeric mechanisms.
van Lengerich B; Agnew C; Puchner EM; Huang B; Jura N
Proc Natl Acad Sci U S A; 2017 Apr; 114(14):E2836-E2845. PubMed ID: 28320942
[TBL] [Abstract][Full Text] [Related]
23. Structures of the HER2-HER3-NRG1β complex reveal a dynamic dimer interface.
Diwanji D; Trenker R; Thaker TM; Wang F; Agard DA; Verba KA; Jura N
Nature; 2021 Dec; 600(7888):339-343. PubMed ID: 34759323
[TBL] [Abstract][Full Text] [Related]
24. Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models.
Wu Y; Zhang Y; Wang M; Li Q; Qu Z; Shi V; Kraft P; Kim S; Gao Y; Pak J; Youngster S; Horak ID; Greenberger LM
Mol Cancer Ther; 2013 Apr; 12(4):427-37. PubMed ID: 23395887
[TBL] [Abstract][Full Text] [Related]
25. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
[TBL] [Abstract][Full Text] [Related]
26. Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers.
Choi B; Cha M; Eun GS; Lee DH; Lee S; Ehsan M; Chae PS; Heo WD; Park Y; Yoon TY
Elife; 2020 Apr; 9():. PubMed ID: 32267234
[TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway.
Rosell R; Taron M; Reguart N; Isla D; Moran T
Clin Cancer Res; 2006 Dec; 12(24):7222-31. PubMed ID: 17189393
[TBL] [Abstract][Full Text] [Related]
28. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor.
Zhang X; Gureasko J; Shen K; Cole PA; Kuriyan J
Cell; 2006 Jun; 125(6):1137-49. PubMed ID: 16777603
[TBL] [Abstract][Full Text] [Related]
29. Profiling epidermal growth factor receptor and heregulin receptor 3 heteromerization using receptor tyrosine kinase heteromer investigation technology.
Ayoub MA; See HB; Seeber RM; Armstrong SP; Pfleger KD
PLoS One; 2013; 8(5):e64672. PubMed ID: 23700486
[TBL] [Abstract][Full Text] [Related]
30. Pan-HER-An antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand-induced EGFR homo- and heterodimers.
Ellebaek S; Brix S; Grandal M; Lantto J; Horak ID; Kragh M; Poulsen TT
Int J Cancer; 2016 Nov; 139(9):2095-105. PubMed ID: 27342948
[TBL] [Abstract][Full Text] [Related]
31. EGFR family: structure physiology signalling and therapeutic targets.
Burgess AW
Growth Factors; 2008 Oct; 26(5):263-74. PubMed ID: 18800267
[TBL] [Abstract][Full Text] [Related]
32. Novel agents that downregulate EGFR, HER2, and HER3 in parallel.
Ferreira RB; Law ME; Jahn SC; Davis BJ; Heldermon CD; Reinhard M; Castellano RK; Law BK
Oncotarget; 2015 Apr; 6(12):10445-59. PubMed ID: 25865227
[TBL] [Abstract][Full Text] [Related]
33. Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells.
Kang JC; Poovassery JS; Bansal P; You S; Manjarres IM; Ober RJ; Ward ES
MAbs; 2014; 6(2):340-53. PubMed ID: 24492289
[TBL] [Abstract][Full Text] [Related]
34. Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis.
Riese DJ; Gallo RM; Settleman J
Bioessays; 2007 Jun; 29(6):558-65. PubMed ID: 17508401
[TBL] [Abstract][Full Text] [Related]
35. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A
Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500
[TBL] [Abstract][Full Text] [Related]
36. Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization.
Shan Y; Eastwood MP; Zhang X; Kim ET; Arkhipov A; Dror RO; Jumper J; Kuriyan J; Shaw DE
Cell; 2012 May; 149(4):860-70. PubMed ID: 22579287
[TBL] [Abstract][Full Text] [Related]
37. Molecular dynamics analysis of conserved hydrophobic and hydrophilic bond-interaction networks in ErbB family kinases.
Shih AJ; Telesco SE; Choi SH; Lemmon MA; Radhakrishnan R
Biochem J; 2011 Jun; 436(2):241-51. PubMed ID: 21426301
[TBL] [Abstract][Full Text] [Related]
38. Molecular pathways: HER3 targeted therapy.
Gala K; Chandarlapaty S
Clin Cancer Res; 2014 Mar; 20(6):1410-6. PubMed ID: 24520092
[TBL] [Abstract][Full Text] [Related]
39. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.
Amin DN; Campbell MR; Moasser MM
Semin Cell Dev Biol; 2010 Dec; 21(9):944-50. PubMed ID: 20816829
[TBL] [Abstract][Full Text] [Related]
40. HER3/ErbB3, an emerging cancer therapeutic target.
Zhang N; Chang Y; Rios A; An Z
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):39-48. PubMed ID: 26496898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
